Morris Medical International, Ltd. (“MMI”) is a high-margin healthcare holding company selling “best-in-class”solutions. We leverage the latest artificial intelligence technologies to provide novel healthcare solutions that significantly reduce treatment costs and increase the quality of life for patients. Currently, we have two products that are in the early phases of marketing: 1) an exceptionally accurate and non-invasive prostate cancer test and 2) a cancer treatment analytics program offering rich and high-probability analytics. 

MMI, in conjunction with our founding partner, have an international network of leading decision makers in both government and business. Together, we routinely engage with a growing list of 40+ health and defense ministers across the globe. MMI forms partnerships via high profile locals who can navigate the governmental, political, regulatory, and cultural complexities unique to each national market. Our key leadership has over 145 years of global experience in the following areas: business, international partnerships, AI software development, international legal and political affairs, financial capital markets, and international intelligence and strategies.

Learn More About the MMI Leadership Team

What we do

Increase sales through
our distributor network
  • Expand your distribution through our vast network.
  • Create strong long-term relationships with distributor management.
  • Manage end-user sales calls.
Train local distributors
and end-users
  • Manager distributor sales meetings and training sessions.
  • Conduct product demonstrations.
  • Assist in problem-solving for distributors & end-users on
    technical product issues.
Provide market-specific support
  • Provide best-in-class user support.
  • Ensure constant communication with our software and technology partners.
  • Maintain fast and efficient communications with distributors
    and end-users.

Our solutions

mir Sentinel™

An FDA Designated Breakthrough Device owned by MiRNA Scientific, Inc. that detects the presence of prostate cancer and accurately assesses the cancer’s aggressiveness using a simple non-invasive urine sample. The Sentinel Test has demonstrated a 97% sensitivity for patients with pathobiological evidence of prostate cancer. The traditional PSA test, MRI, and biopsy combination has just a 44% sensitivity level; making it highly inaccurate, invasive, and potentially leading to impotence, incontinence, infection, and over-treatment.

Learn More About mir Sentinel™
CLICK HERE TO ORDER THE SENTINEL TEST

Contact us

To request a consultation or discover more about our services and solutions, please reach us via email or click the link below and complete our online contact form.

        Contact Us